Coordinated expression of galectin-3 and caveolin-1 in thyroid cancer

Journal of Pathology

Volumn 228, Issue 1, 2012, Pages 56-66

  Shankar, Jay ^a   Wiseman, Sam M ^a   Meng, Fanrui ^a   Kasaian, Katayoon ^b   Strugnell, Scott ^a   Mofid, Alireza ^a   Gown, Allen ^a,c   Jones, Steven J M ^a,b   Nabi, Ivan R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c PHENOPATH LABORATORIES   (United States)

Author keywords

caveolin 1; focal adhesions; galectin 3; thyroid cancer; tissue microarray; tumour cell migration

Indexed keywords

CAVEOLIN 1; FOCAL ADHESION KINASE; GALECTIN 3; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA;

ANAPLASTIC THYROID CANCER; ARTICLE; BENIGN TUMOR; CANCER CELL; CANCER GROWTH; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; ENZYME ACTIVATION; ENZYME STABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; WESTERN BLOTTING;

ADENOMA; CAVEOLIN 1; CELL LINE, TUMOR; DISEASE PROGRESSION; GALECTIN 3; GENE KNOCKDOWN TECHNIQUES; GOITER; HASHIMOTO DISEASE; HUMANS; RNA, SMALL INTERFERING; THYROID NEOPLASMS; THYROID NODULE; THYROIDITIS, AUTOIMMUNE; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84864749445     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4041     Document Type: Article

References (39)

1. Goetz JG, Lajoie P, Wiseman SM, et al., Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metast Rev 2008; 27: 715-735.
2. Williams TM, Lisanti MP,. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005; 288: C494-506.
3. Lajoie P, Partridge EA, Guay G, et al., Plasma membrane domain organization regulates EGFR signaling in tumor cells. J Cell Biol 2007; 179: 341-356.
4. Goetz J, Joshi B, Lajoie P, et al., Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosine phosphorylated caveolin-1. J Cell Biol 2008; 180: 1261-1275.
5. Joshi B, Strugnell SS, Goetz JG, et al., Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res 2008; 68: 8210-8220.
6. Grande-Garcia A, Echarri A, de Rooij J, et al., Caveolin-1 regulates cell polarization and directional migration through Src kinase and Rho GTPases. J Cell Biol 2007; 177: 683-694.
7. Arpaia E, Blaser H, Quintela-Fandino M, et al., The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of α5-integrin and the activation of Src, Ras and Erk. Oncogene 2011; 31: 884-896.
8. Partridge EA, Le Roy C, Di Guglielmo GM, et al., Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 2004; 306: 120-124.
9. Dennis JW, Lau KS, Demetriou M, et al., Adaptive regulation at the cell surface by N-glycosylation. Traffic 2009; 10: 1569-1578.
10. Lau K, Partridge EA, Silvescu CI, et al., Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 2007; 129: 123-124.
11. Lajoie P, Goetz JG, Dennis JW, et al., Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane. J Cell Biol 2009; 185: 381-385.
12. Davies L, Welch HG,. Increasing incidence of thyroid cancer in the United States, 1973-2002. J Am Med Assoc 2006; 295: 2164-2167.
13. LiVolsi VA, Asa SL,. The demise of follicular carcinoma of the thyroid gland. Thyroid 1994; 4: 233-236.
14. Cooper DS, Doherty GM, Haugen BR, et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
15. Nilubol N, Kebebew E,. Personalizing thyroid cancer care: are we there yet? Ann Surg Oncol 2011; 18: 1819-1820.
16. O'Neill JP, Power D, Condron C, et al., Anaplastic thyroid cancer, tumorigenesis and therapy. Ir J Med Sci 2010; 179: 9-15.
17. Wiseman SM, Loree TR, Rigual NR, et al., Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck 2003; 25: 662-670.
18. Kojic SL, Strugnell SS, Wiseman SM,. Anaplastic thyroid cancer: a comprehensive review of novel therapy. Expert Rev Anticancer Ther 2011; 11: 387-402.
19. Xu XC, el-Naggar AK, Lotan R,. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 1995; 147: 815-822.
20. Takenaka Y, Inohara H, Yoshii T, et al., Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett 2003; 195: 111-119.
21. Yoshii T, Inohara H, Takenaka Y, et al., Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 2001; 18: 787-792.
22. Wiseman SM, Melck A, Masoudi H, et al., Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol 2008; 15: 2811-2826.
23. Chiu CG, Strugnell SS, Griffith OL, et al., Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010; 176: 2067-2081.
24. Inohara H, Honjo Y, Yoshii T, et al., Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 1999; 85: 2475-2484.
25. Bartolazzi A, Gasbarri A, Papotti M, et al., Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroidlesions. Lancet 2001; 357: 1644-1650.
26. Bartolazzi A, Orlandi F, Saggiorato E, et al., Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol 2008; 9: 543-549.
27. Wiseman SM, Masoudi H, Niblock P, et al., Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 2007; 14: 719-729.
28. Parker RL, Huntsman DG, Lesack DW, et al., Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 2002; 117: 723-728.
29. Wiseman SM, Griffith OL, Deen S, et al., Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg 2007; 142: 717-727; discussion, 727-719.
30. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289-300.
31. Shankar J, Messenberg A, Chan J, et al., Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Cancer Res 2010; 70: 3780-3790.
32. Hamadi A, Bouali M, Dontenwill M, et al., Regulation of focal adhesion dynamics and disassembly by phosphorylation of FAK at tyrosine 397. J Cell Sci 2005; 118: 4415-4425.
33. Ito Y, Yoshida H, Nakano K, et al., Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid. Br J Cancer 2002; 86: 912-916.
34. Lajoie P, Nabi IR,. Regulation of raft-dependent endocytosis. J Cell Mol Med 2007; 11: 644-653.
35. Wiseman SM, Griffith OL, Gown A, et al., Immunophenotyping of thyroid tumors identifies molecular markers altered during transformation of differentiated into anaplastic carcinoma. Am J Surg 2011; 201: 578-584.
36. Lagana A, Goetz JG, Cheung P, et al., Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells. Mol Cell Biol 2006; 26: 3181-3193.
37. Schweppe RE, Kerege AA, French JD, et al., Inhibition of Src with AZD0530 reveals the Src-focal adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab 2009; 94: 2199-2203.
38. Nangia-Makker P, Hogan V, Honjo Y, et al., Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. JNCI Cancer Spectrum 2002; 94: 1854-1862.
39. Lin CI, Whang EE, Donner DB, et al., Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res 2009; 7: 1655-1662.